Prognostic value of clonal evolution identified by sequential FISH in untreated chronic lymphocytic leukaemia

Abstract

Aim: The aim of the current study was to evaluate the potential clinical impact of clonal evolution detected by fluorescence in situ hybridization (FISH) in untreated chronic lymphocytic leukaemia (CLL) patients managed with a watch-and-wait strategy.

Methods: We performed both overall survival (OS) and time to first treatment (TTFT) analysis. For the first one, we exploited a real-life cohort of 123 consecutive CLL patients followed at our institution, for which at least a second FISH evaluation during watch and wait was available. For TTFT analysis, we considered only patients treated after the second FISH sample (n = 69).

Results: Considering the original cohort, patients who acquired a FISH abnormality displayed a worse outcome with a median OS of 91.9 months compared to 147.3 months for patients who did not acquire any FISH abnormalities (P = 0.007). Unmutated immunoglobulin heavy chain gene (IGHV) genes were associated with a higher probability of acquiring a FISH abnormality (P = 0.04). Turning to TTFT analysis, patients who gained at least one FISH abnormality (n = 7, 10%) were characterised by an earlier treatment requirement with a median TTFT of 1.1 months, compared to 2.7 months in patients who did not acquire any FISH abnormalities (n = 62, 90%) (P = 0.025).

Conclusions: The dynamic acquisition of karyotypic abnormalities by FISH predicts poor outcomes and early treatment requirement in CLL patients. Our results suggest that FISH analysis could be integrated with other clinical and biological features to obtain dynamic scores that are able to predict outcomes at different phases of disease history.

Keywords

Chronic lymphocytic leukaemia / FISH analysis / clonal evolution

References

[1] Kay NE,Van Dyke DL.CLL update 2022: a continuing evolution in care.Blood Rev2022;54:100930

[2] Siegel RL,Fuchs HE.Cancer statistics, 2022.CA Cancer J Clin2022;72:7-33

[3] Smith A,Patmore R,Roman E.Incidence of haematological malignancy by sub-type: a report from the Haematological malignancy research network.Br J Cancer2011;105:1684-92 PMCID:PMC3242607

[4] Köhnke T,Bücklein VL.Diagnosis of CLL revisited: increased specificity by a modified five-marker scoring system including CD200.Br J Haematol2017;179:480-7

[5] Rai KR,Cronkite EP,Levy RN.Clinical staging of chronic lymphocytic leukemia.Blood1975;46:219-34.

[6] Binet JL,Dighiero G.A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis.Cancer1981;48:198-206

[7] Condoluci A,Langerbeins P.International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia.Blood2020;135:1859-69

[8] Cohen JA,Zucchetto A.A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia.Haematologica2020;105:1613-20 PMCID:PMC7271568

[9] Döhner H,Benner A.Genomic aberrations and survival in chronic lymphocytic leukemia.N Engl J Med2000;343:1910-6

[10] Hallek M.Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures.Am J Hematol2021;96:1679-705

[11] Landau DA,Taylor-Weiner AN.Mutations driving CLL and their evolution in progression and relapse.Nature2015;526:525-30 PMCID:PMC4815041

[12] Gruber M,Leshchiner I.Growth dynamics in naturally progressing chronic lymphocytic leukaemia.Nature2019;570:474-9 PMCID:PMC6630176

[13] Huang SJ,Smith AC.Clonal evolution as detected by interphase fluorescence in situ hybridization is associated with worse overall survival in a population-based analysis of patients with chronic lymphocytic leukemia in British Columbia, Canada.Cancer Genet2017;210:1-8

[14] Ramassone A,Veronese A.Genetic dynamics in untreated CLL patients with either stable or progressive disease: a longitudinal study.J Hematol Oncol2019;12:114 PMCID:PMC6862808

[15] Leeksma AC,Wu B.Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia.Leukemia2019;33:390-402 PMCID:PMC6718955